Immunogenicity and pharmacokinetic studies of recombinant Factor VIII containing lipid cochleates

Replacement therapy using recombinant factor VIII (rFVIII) is currently the most common therapy for hemophilia A, a bleeding disorder caused by the deficiency of FVIII. However, 15–30% of patients develop inhibitory antibodies against administered rFVIII which complicates the therapy. Encapsulation...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Kosloski, Matthew P., Peng, Aaron, Varma, Prashant R., Fathallah, Anas M., Miclea, Razvan D., Mager, Donald E., Balu-Iyer, Sathy V.
Format: Artigo
Langue:Inglês
Publié: 2010
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3068242/
https://ncbi.nlm.nih.gov/pubmed/21114461
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10717544.2010.536269
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires